

INDEVUS PHARMACEUTICALS INC  
Form 4  
December 08, 2008

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
ROGERS MICHAEL W

2. Issuer Name and Ticker or Trading Symbol  
INDEVUS PHARMACEUTICALS INC [IDEV]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)

(Last) (First) (Middle)  
33 HAYDEN AVENUE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
12/04/2008

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
Executive Vice President

LEXINGTON, MA 02421

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  |                                | (A) or (D)  | Code V Amount (D) Price   |  |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security | 2. Conversion or Exercise | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any | 4. Transaction Code | 5. Number of Derivative Securities Acquired (A) or | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) |
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|--|--|---|
|---------------------------------|---------------------------|--------------------------------------|-----------------------------------|---------------------|--|--|---|

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 4

| (Instr. 3)                  | Price of Derivative Security | (Month/Day/Year) | (Instr. 8)       | Disposed of (D)      |         | Date Exercisable | Expiration Date | Title      | Am<br>Nur<br>Sha                         |    |
|-----------------------------|------------------------------|------------------|------------------|----------------------|---------|------------------|-----------------|------------|--|----|
|                             |                              |                  |                  | (Instr. 3, 4, and 5) |         |                  |                 |            |  |    |
|                             |                              |                  | Code             | V                    | (A)     | (D)              |                 |            |  |    |
| Stock Option (Right to Buy) | \$ 6                         | 12/04/2008       | D <sup>(1)</sup> |                      |         | 125,000          | <sup>(2)</sup>  | 10/05/2009 | Common Stock, \$0.01 par value per share | 12 |
| Stock Option (Right to Buy) | \$ 6                         | 12/04/2008       | A <sup>(1)</sup> |                      | 125,000 |                  | <sup>(3)</sup>  | 10/05/2010 | Common Stock, \$0.01 par value per share | 12 |
| Stock Option (Right to Buy) | \$ 4                         | 12/04/2008       | D <sup>(1)</sup> |                      |         | 250,000          | <sup>(2)</sup>  | 10/05/2009 | Common Stock, \$0.01 par value per share | 25 |
| Stock Option (Right to Buy) | \$ 4                         | 12/04/2008       | A <sup>(1)</sup> |                      | 250,000 |                  | <sup>(3)</sup>  | 10/05/2010 | Common Stock, \$0.01 par value per share | 25 |

## Reporting Owners

| Reporting Owner Name / Address                              | Relationships |           |                          |       |
|---|---------------|-----------|--------------------------|-------|
|   | Director      | 10% Owner | Officer                  | Other |
| ROGERS MICHAEL W<br>33 HAYDEN AVENUE<br>LEXINGTON, MA 02421 |               |           | Executive Vice President |       |

## Signatures

Michael W. Rogers  
12/08/2008

    Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

All of the reported transactions involved the amendment of outstanding stock options to extend the respective expiration dates from (1) 10/5/2009 to 10/5/2010; such extensions are considered by the Securities and Exchange Commission to be cancellations of the current stock options.

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 4

- (2) Prior to the extension of the current stock option, such stock option was fully exercisable.
- (3) This stock option is fully exercisable as of the date of this report.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.